Detailed FundamentalsSingle-page fundamentals layout — broad valuation, growth, profitability, health, competitors, top funds & analyst detail.
Price chartUnavailable
Loading price history...
52-Week Range
Trailing twelve months
$45.80$61.70
1-Month Range
Month up 8.8%
$46.27$51.54
Daily Price Range
Day down -1.8%
$49.79$50.36
Volume
vs 5M avg
1M5M avg
Profile
Identity and capital structure
SectorUnclassified
IndustryCommon Stock
Market Cap$100.4B
Short % of Float—
Employees—
Sales$32,667M
Shares Outstanding2,004,469,591
IPO Date—
Last Reported Qtr.—
Next Qtr. Report—
Headquarters—
Homepagewww.gsk.com
GSK plc — GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RS….· via yahoo
Warnings
1 signal
Live
- Current ratio below 1 (0.86)
Scores
0–100 · higher is better except where noted · Insider Sent: directional buy ratio (excl. gifts/grants)
Value
93
Growth
78
Quality
87
Sentiment
63
Insider Sent.
—
Piotroski F
—
Altman Z
—
Consensus rating unavailable — no analyst coverage on file for GSK.
Price targets unavailable — no 12-month targets on file for GSK.
Valuation Engine
DCF Intrinsic Valuation Model
Run an interactive 5-year Discounted Cash Flow valuation on GSK, calculate Margin of Safety, and stress-test WACC discount hurdles.
RetrievedQuote: Live · Insiders: Live · Fundamentals/Benchmarks: Curated · Vantage Composite · 1 warnings surfacedNov 11, 2026, 6:55 PM UTC